The ongoing pursuit of neuroprotective therapies in Parkinson disease

Nature Reviews Neurology

Volumn 11, Issue 1, 2015, Pages 25-40

  Athauda, Dilan ^a   Foltynie, Thomas ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMYLOID BETA PROTEIN; ANTIPARKINSON AGENT; AZD 3241; BIOLOGICAL MARKER; CERE 120; CREATINE; DEFERIPRONE; DIMEBON; ELN 484228; ENZYME INHIBITOR; ERYTHROPOIETIN; EXENDIN 4; GRANULOCYTE COLONY STIMULATING FACTOR; INOSINE; ISRADIPINE; METFORMIN; MITOQUINONE; NICOTINE; OMIGAPIL; PIOGLITAZONE; PLACEBO; PYM 50028; RASAGILINE; RESVERATROL; TAU PROTEIN; UBIDECARENONE; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT;

COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DRUG DEVELOPMENT; DRUG EFFICACY; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; COGNITION DISORDERS; COMPLICATION;

COGNITION DISORDERS; DRUG DISCOVERY; HUMANS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PARKINSON DISEASE;

EID: 84924042444     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.226     Document Type: Review

References (220)

1. Duncan, G. W. et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov. Disord. 29, 195-202 (2014).
2. Lawson, R. A. et al. Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism Relat. Disord. 20, 1071-1075 (2014).
3. Hirsch, E. C., Jenner, P. & Przedborski, S. Pathogenesis of Parkinson's disease. Mov. Disord. 28, 24-30 (2013).
4. Schapira, A. H. V. & Tolosa, E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6, 309-317 (2010).
5. Foltynie, T. & Kahan, J. Parkinson's disease: an update on pathogenesis and treatment. J. Neurol. 260, 1433-1440 (2013).
6. Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T. & Bezard, E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384, 545-555 (2014).
7. Olanow, C. W. & Kordower, J. H. Modeling Parkinson's disease. Ann. Neurol. 66, 432-436 (2009).
8. Blandini, F. & Armentero, M.-T. Animal models of Parkinson's disease. FEBS J. 279, 1156-1166 (2012).
9. Bezard, E., Yue, Z., Kirik, D. & Spillantini, M. G. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov. Disord. 28, 61-70 (2013).
10. Pifl, C., Schingnitz, G. & Hornykiewicz, O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44, 591-605 (1991).
11. Mounayar, S. et al. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130, 2898-2914 (2007).
12. Iravani, M. M. et al. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur. J. Neurosci. 21, 841-854 (2005).
13. Duty, S. & Jenner, P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 164, 1357-1391 (2011).
14. Ekstrand, M. I. & Galter, D. The MitoPark Mouse-an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat. Disord. 15 (Suppl. 3), S185-S188 (2009).
15. Volpicelli-Daley, L. A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71 (2011).
16. Luk, K. C. & Lee, V. M. Modeling Lewy pathology propagation in Parkinson's disease. Parkinsonism Relat. Disord. 20 (Suppl. 1), S85-S87 (2014).
17. Fahn, S. et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498-2508 (2004).
18. Lang, A. E., Melamed, E., Poewe, W. & Rascol, O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov. Disord. 28, 86-95 (2013).
19. D'Agostino, R. B. Sr. The delayed-start study design. N. Engl. J. Med. 361, 1304-1306 (2009).
20. Elm, J. J. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1. Mov. Disord. 27, 1513-1521 (2012).
21. Fearnley, J. M. & Lees, A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283-2301 (1991).
22. Kordower, J. H. et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136, 2419-2431 (2013).
23. Schwingenschuh, P. et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov. Disord. 25, 560-569 (2010).
24. Foltynie, T., Brayne, C. & Barker, R. A. The heterogeneity of idiopathic Parkinson's disease. J. Neurol. 249, 138-145 (2002).
25. Dragalin, V. An introduction to adaptive designs and adaptation in CNS trials. Eur. Neuropsychopharmacol. 21, 153-158 (2011).
26. 181, and α-synuclein levels with clinical features of drug- naive patients with early Parkinson disease. JAMA Neurol. 70, 1277-1287 (2013).
27. Agarwal, P. A. & Stoessl, A. J. Biomarkers for trials of neuroprotection in Parkinson's disease. Mov. Disord. 28, 71-85 (2013).
28. Olanow, C. W. et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 5, 1013-1020 (2006).
29. Ward, C. D. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J. Neurol. Neurosurg. Psychiatry 57, 217-220 (1994).
30. Sherer, T. B., Chowdhury, S., Peabody, K. & Brooks, D. W. Overcoming obstacles in Parkinson's disease. Mov. Disord. 27, 1606-1611 (2012).
31. Tardiff, D. F. et al. Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science 342, 979-983 (2013).
32. Chung, C. Y. et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 342, 983-987 (2013).
33. Mortiboys, H., Aasly, J. & Bandmann, O. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain 136, 3038-3050 (2013).
34. Chan, C. S., Gertler, T. S. & Surmeier, D. J. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov. Disord. 25 (Suppl. 1), S63-S70 (2010).
35. V1 channels and calcium-binding proteins. Brain 136, 2077-2097 (2013).
36. Becker, C., Jick, S. S. & Meier, C. R. Use of antihypertensives and the risk of Parkinson disease. Neurology 70, 1438-1444 (2008).
37. Ritz, B. et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600-606 (2010).
38. Pasternak, B. et al. Use of calcium channel blockers and Parkinson's disease. Am. J. Epidemiol. 175, 627-635 (2012).
39. Marras, C. et al. Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann. Neurol. 71, 362-369 (2012).
40. Ilijic, E., Guzman, J. N. & Surmeier, D. J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis. 43, 364-371 (2011).
41. Chan, C. S. et al. "Rejuvenation" protects neurons in mouse models of Parkinson's disease. Nature 447, 1081-1086 (2007).
42. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease- modifying intervention in early Parkinson's disease (STEADY-PD). Mov. Disord. 28, 1823-1831 (2013).
43. Kang, S. et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat. Commun. 3, 1146 (2012).
44. Okada, M. et al. Exocytosis mechanism as a new targeting site for mechanisms of action of antiepileptic drugs. Life Sci. 72, 465-473 (2002).
45. Mochio, S. et al. Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson's disease. Parkinsonism Relat. Disord. 18, 906-908 (2012).
46. Asanuma, M. et al. Neuroprotective effects of zonisamide target astrocyte. Ann. Neurol. 67, 239-249 (2010).
47. Alam, Z. I. et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1196-1203 (1997).
48. Pålhagen, S. et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66, 1200-1206 (2006).
49. Olanow, C. W. et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268-1278 (2009).
50. Weisskopf, M. G., O'Reilly, E., Chen, H., Schwarzschild, M. A. & Ascherio, A. Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166, 561-567 (2007).
51. Alonso, A., Rodríguez, L. A. G., Logroscino, G. & Hernán, M. A. Gout and risk of Parkinson disease: a prospective study. Neurology 69, 1696-1700 (2007).
52. Shen, C., Guo, Y., Luo, W., Lin, C. & Ding, M. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can. J. Neurol. Sci. 40, 73-79 (2013).
53. Schwarzschild, M. A. et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 65, 716-723 (2008).
54. Ascherio, A. et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66, 1460-1468 (2009).
55. Andreadou, E. et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin. Neurol. Neurosurg. 111, 724-728 (2009).
56. Yamamoto, T. et al. Effect of inosine on the plasma concentration of uridine and purine bases. Metabolism 51, 438-442 (2002).
57. Schwarzschild, M. A. et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 71, 141-150 (2014).
58. Grayson, P. C., Kim, S. Y., LaValley, M. & Choi, H. K. Hyperuricemia and incident hypertension: a systematic review and meta- analysis. Arthritis Care Res. (Hoboken) 63, 102-110 (2011).
59. Takanashi, M. et al. Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). Parkinsonism Relat. Disord. 7, 311-314 (2001).
60. Sian-Hülsmann, J., Mandel, S., Youdim, M. B. & Riederer, P. The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem. 118, 939-957 (2011).
61. nd edn Vol. 1 Ch. 6 148-153 (John Wiley & Sons, 2014).
62. Jamuar, S. S. & Lai, A. H. Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther. Adv. Hematol. 3, 299-307 (2012).
63. Molina-Holgado, F., Gaeta, A., Francis, P. T., Williams, R. J. & Hider, R. C. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J. Neurochem. 105, 2466-2476 (2008).
64. Dexter, D. T. et al. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J. Neural Transm. 118, 223-231 (2011).
65. Devos, D. et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal. 21, 195-210 (2014).
66. Hauser, R. A., Lyons, K. E., McClain, T., Carter, S. & Perlmutter, D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov. Disord. 24, 979-983 (2009).
67. Chinta, S. J. & Andersen, J. K. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic. Biol. Med. 41, 1442-1448 (2006).
68. Sian, J. et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348-355 (1994).
69. Riederer, P. et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520 (1989).
70. Dexter, D. T. et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35, 38-44 (1994).
71. Hauser, R. A., Lyons, K. E., McClain, T., Carter, S. & Perlmutter, D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov. Disord. 24, 979-983 (2009).
72. Clark, J. et al. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in α-synuclein overexpressing mice. PLoS ONE 5, e12333 (2010).
73. Katz, M., Swanson, R. A., Glass, G. A. Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration: phase I trial in Parkinson's disease [abstract 664]. Mov. Disord. 29 (Suppl. 1), S247 (2014).
74. Adair, J. C., Knoefel, J. E. & Morgan, N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57, 1515-1517 (2001).
75. Schapira, A. H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7, 97-109 (2008).
76. Tain, L. S. et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12, 1129-1135 (2009).
77. Carta, A. R. & Pisanu, A. Modulating microglia activity with PPAR-ã agonists: a promising therapy for Parkinson's disease? Neurotox. Res. 23, 112-123 (2013).
78. Khan, M. M. et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 1328, 139-151 (2010).
79. Lofrumento, D. D. et al. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun. 20, 249-260 (2014).
80. Rees, K. et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD008454. http://dx.doi.org/10.1002/14651858.CD008454.pub2.
81. Bartels, A. L. et al. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat. Disord. 16, 57-59 (2010).
82. Imamura, K. et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 106, 518-526 (2003).
83. International Parkinson's Disease Genomics Consortium (IPDGC) & Wellcome Trust Case Control Consortium 2 (WTCCC2). A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet. 7, e1002142 (2011).
84. Diani, A. R., Sawada, G., Wyse, B., Murray, F. T. & Khan, M. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 286, E116-E122 (2004).
85. Heneka, M. T. et al. Acute treatment with the PPARã agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453 (2005).
86. Okada, K., Yamashita, U. & Tsuji, S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice. Brain Res. 1102, 175-178 (2006).
87. Nakamura, T. et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 38, 3016-3022 (2007).
88. Schütz, B. et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25, 7805-7812 (2005).
89. Dehmer, T., Heneka, M. T., Sastre, M., Dichgans, J. & Schulz, J. B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IêB alpha induction and block of NFêB and iNOS activation. J. Neurochem. 88, 494-501 (2004).
90. Breidert, T. et al. Protective action of the peroxisome proliferator-activated receptor-ã agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82, 615-624 (2002).
91. Swanson, C. R. et al. The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J. Neuroinflammation 8, 91 (2011).
92. Suzuki, S. et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol. Sci. 113, 349-357 (2010).
93. Azoulay, L. et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344, e3645 (2012).
94. Ferwana, M. et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet. Med. 30, 1026-1032 (2013).
95. Consoli, A. & Formoso, G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes Obes. Metab. 15, 967-977 (2013).
96. Colca, J. R. et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE 8, e61551 (2013).
97. Colca, J. R. et al. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. 286, E252-E260 (2004).
98. Colca, J. R. et al. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin. Pharmacol. Ther. 93, 352-359 (2013).
99. Appel, S. H. Inflammation in Parkinson's disease: cause or consequence? Mov. Disord. 27, 1075-1077 (2012).
100. Choi, D.-K. et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 25, 6594-6600 (2005).
101. Posener, J. A., et al. Safety, tolerability, and pharmacodynamics of AZD3241, a myeloperoxidase inhibitor, in Parkinson's disease [abstract 698]. Mov. Disord. 29 (Suppl. 1), S259-S260 (2014).
102. Selley, M. L. Simvastatin prevents 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 1037, 1-6 (2005).
103. Wang, Q., Wang, P. H., McLachlan, C. & Wong, P. T. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 1045, 229-233 (2005).
104. Hernández-Romero, M. C. et al. Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J. Neurochem. 105, 445-459 (2008).
105. + does not. Eur. J. Pharmacol. 609, 58-64 (2009).
106. Yan, J., Sun, J., Huang, L., Fu, Q. & Du, G. Simvastatin prevents neuroinflammation by inhibiting N-methyl-d-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells. J. Neurosci. Res. 92, 634-640 (2014).
107. Bar-On, P. et al. Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson's disease. J. Neurochem. 105, 1656-1667 (2008).
108. Gao, X., Simon, K. C., Schwarzschild, M. A. & Ascherio, A. Prospective study of statin use and risk of Parkinson disease. Arch. Neurol. 69, 380-384 (2012).
109. Wahner, A. D., Bronstein, J. M., Bordelon, Y. M. & Ritz, B. Statin use and the risk of Parkinson disease. Neurology 70, 1418-1422 (2008).
110. Wolozin, B. et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 5, 20 (2007).
111. Becker, C., Jick, S. S. & Meier, C. R. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf. 31, 399-407 (2008).
112. Hippisley-Cox, J. & Coupland, C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340, c2197 (2010).
113. Ritz, B. et al. Statin use and Parkinson's disease in Denmark. Mov. Disord. 25, 1210-1216 (2010).
114. Huang, X. et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov. Disord. 22, 377-381 (2007).
115. Lee, Y.-C. et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 81, 410-416 (2013).
116. Martin, F. L., Williamson, S. J., Paleologou, K. E., Allsop, D. & El-Agnaf, O. M. α-Synuclein and the pathogenesis of Parkinson's disease. Protein Pept. Lett. 11, 229-237 (2004).
117. Li, J.-Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503 (2008).
118. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106, 13010-13015 (2009).
119. Hansen, C. et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715-725 (2011).
120. Mougenot, A.-L. et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225-2228 (2012).
121. Tóth, G. et al. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS ONE 9, e87133 (2014).
122. Masliah, E. et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857-868 (2005).
123. Masliah, E. et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6, e19338 (2011).
124. Schneeberger, a, Mandler, M., Mattner, F. & Schmidt, W. Vaccination for Parkinson's disease. Parkinsonism Relat. Disord. 18 (Suppl. 1), S11-S13 (2012).
125. Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752 (2006).
126. Lee, K.-W. et al. Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J. Neurosci. 31, 6963-6971 (2011).
127. Pérez-Revuelta, B. I. et al. Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis. 5, e1209 (2014).
128. Wahlqvist, M. L. et al. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat. Disord. 18, 753-758 (2012).
129. Steele, J. W. et al. Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Mol. Psychiatry 18, 882-888 (2013).
130. Duran, R. et al. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov. Disord. 28, 232-236 (2013).
131. Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783-1794 (2009).
132. Sardi, S. P. et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher- related synucleinopathies. Proc. Natl Acad. Sci. USA 110, 3537-3542 (2013).
133. Zimran, A., Altarescu, G. & Elstein, D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol. Dis. 50, 134-137 (2013).
134. Bendikov-Bar, I., Maor, G., Filocamo, M. & Horowitz, M. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50, 141-145 (2013).
135. Olanow, C. W. & Schapira, A. H. Therapeutic prospects for Parkinson disease. Ann. Neurol. 74, 337-347 (2013).
136. Richter, F. et al. A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics 11, 840-856 (2014).
137. Wu, G., Lu, Z.-H., Kulkarni, N., Amin, R. & Ledeen, R. W. Mice lacking major brain gangliosides develop parkinsonism. Neurochem. Res. 36, 1706-1714 (2011).
138. Schneider, J. S. et al. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 256, 843-846 (1992).
139. Schneider, J. S., Sendek, S., Daskalakis, C. & Cambi, F. GM1 ganglioside in Parkinson's disease: results of a five year open study. J. Neurol. Sci. 292, 45-51 (2010).
140. Schneider, J. S. et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J. Neurol. Sci. 324, 140-148 (2013).
141. Parkes, D. G., Mace, K. F. & Trautmann, M. E. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin. Drug Discov. 8, 219-244 (2013).
142. Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M. & Greig, N. H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 302, 881-888 (2002).
143. Perry, T. et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958-966 (2002).
144. Harkavyi, A. et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation 5, 19 (2008).
145. Kim, S., Moon, M. & Park, S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 202, 431-439 (2009).
146. Bertilsson, G. et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86, 326-338 (2008).
147. Rampersaud, N. et al. Exendin-4 reverses biochemical and behavioral deficits in a pre- motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. Neuropeptides 46, 183-193 (2012).
148. Chen, S., Liu, A., An, F., Yao, W. & Gao, X. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr.) 34, 1211-1224 (2012).
149. Aviles-Olmos, I. et al. Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2364-2365 (2013).
150. Aviles-Olmos, I. et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337-444 (2014).
151. Ryan, G. J., Moniri, N. H. & Smiley, D. D. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 70, 1123-1131 (2013).
152. Chang, R. C., Ho, Y.-S., Wong, S., Gentleman, S. M. & Ng, H.-K. Neuropathology of cigarette smoking. Acta Neuropathol. 127, 53-69 (2014).
153. Tsuang, D. et al. Association between lifetime cigarette smoking and Lewy body accumulation. Brain Pathol. 20, 412-418 (2010).
154. Hong, D.-P., Fink, A. L. & Uversky, V. N. Smoking and Parkinson's disease: does nicotine affect α-synuclein fibrillation? Biochim. Biophys. Acta 1794, 282-290 (2009).
155. Quik, M., Perez, X. A. & Bordia, T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov. Disord. 27, 947-957 (2012).
156. Shimohama, S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol. Pharm. Bull. 32, 332-336 (2009).
157. Ward, R. J., Lallemand, F., de Witte, P. & Dexter, D. T. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. Prog. Neurobiol. 85, 135-147 (2008).
158. Costa, G., Abin-Carriquiry, J. A. & Dajas, F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 888, 336-342 (2001).
159. Ryan, R. E., Ross, S. A., Drago, J. & Loiacono, R. E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol. 132, 1650-1656 (2001).
160. Parain, K., Marchand, V., Dumery, B. & Hirsch, E. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res. 890, 347-350 (2001).
161. Quik, M. et al. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- lesioned primates. J. Neurosci. 26, 4681-4689 (2006).
162. Brundin, P. et al. Linked clinical trials-the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J. Parkinsons Dis. 3, 231-239 (2013).
163. Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837-844 (2008).
164. Muslimovic, D., Post, B., Speelman, J. D. & Schmand, B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65, 1239-1245 (2005).
165. Rolinski, M., Fox, C., Maidment, I. & McShane, R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD006504. http://dx.doi.org/ 10.1002/14651858.CD006504.pub2.
166. Broadstock, M., Ballard, C. & Corbett, A. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opin. Pharmacother. 15, 1797-1810 (2014).
167. Irwin, D. J. et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72, 587-598 (2012).
168. Masliah, E. et al. β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 12245-12250 (2001).
169. Jellinger, K. A., Seppi, K., Wenning, G. K. & Poewe, W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J. Neural Transm. 109, 329-339 (2002).
170. Kotzbauer, P. T. et al. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch. Neurol. 69, 1326-1331 (2012).
171. Compta, Y. et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 134, 1493-1505 (2011).
172. Irwin, D. J., Lee, V. M. & Trojanowski, J. Q. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci. 14, 626-636 (2013).
173. Simón-Sánchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312 (2009).
174. Morley, J. F. et al. Genetic influences on cognitive decline in Parkinson's disease. Mov. Disord. 27, 512-518 (2012).
175. Edwards, T. L. et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74, 97-109 (2010).
176. Goris, A. et al. Tau and α-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann. Neurol. 62, 145-153 (2007).
177. Tariot, P. N. et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry 68, 853-861 (2011).
178. Zhang, X. et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer's disease transgenic mouse model. J. Alzheimers. Dis. 24, 739-749 (2011).
179. Nunes, M. A., Viel, T. A. & Buck, H. S. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr. Alzheimer Res. 10, 104-107 (2013).
180. Zhang, B. et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer- like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32, 3601-3611 (2012).
181. Wen, Y. et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J. Biol. Chem. 286, 16504-16515 (2011).
182. O'Leary, J. C. et al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener. 5, 45 (2010).
183. Spires-Jones, T. L. et al. Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci. Lett. 562, 63-68 (2014).
184. Stack, C. et al. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum. Mol. Genet. 23, 3716-3732 (2014).
185. Wischik, C. M., Bentham, P., Wischik, D. J. & Seng, K. M. Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks [abstract]. Alzheimers Dement. 4 (Suppl. 1). T167 (2008).
186. Braak, H., Rüb, U., Jansen Steur, E. N., Del Tredici, K. & de Vos, R. A. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64, 1404-1410 (2005).
187. Hurtig, H. I. et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54, 1916-1921 (2000).
188. Montine, T. J. et al. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25, 2682-2685 (2010).
189. Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. & Kragh-Sørensen, P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60, 387-392 (2003).
190. Selikhova, M. et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 132, 2947-2957 (2009).
191. Weinreb, O., Amit, T., Riederer, P., Youdim, M. B. & Mandel, S. A. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. Int. Rev. Neurobiol. 100, 127-149 (2011).
192. Beal, M. F. Neuroprotective effects of creatine. Amino Acids 40, 1305-1313 (2011).
193. Beal, M. F. et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71, 543-552 (2014).
194. + in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 22, 2488-2497 (2008).
195. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01060878 (2013).
196. Jin, H., Kanthasamy, A., Ghosh, A. & Anantharam, V. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta 1842, 1282-1294 (2013).
197. Snow, B. J. et al. A double-blind, placebo- controlled study to assess the mitochondria- targeted antioxidant MitoQ as a disease- modifying therapy in Parkinson's disease. Mov. Disord. 25, 1670-1674 (2010).
198. Marks, W. J. et al. Gene delivery of AAV2- neurturin for Parkinson's disease: a double- blind, randomised, controlled trial. Lancet Neurol. 9, 1164-1172 (2010).
199. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/ NCT01621581 (2014).
200. Fitton, A. & Benfield, P. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 40, 31-74 (1990).
201. Chen, X. et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc. Natl Acad. Sci. USA 110, 300-305 (2013).
202. Boddaert, N. et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110, 401-408 (2007).
203. Berman, A. E. et al. N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1-/- mouse. Ann. Neurol. 69, 509-520 (2011).
204. Pan, J. et al. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. Neurochem. Int. 54, 418-425 (2009).
205. Choudhury, M. E. et al. Zonisamide-induced long- lasting recovery of dopaminergic neurons from MPTP-toxicity. Brain Res. 1384, 170-178 (2011).
206. Choudhury, M. E. et al. Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors. Eur. J. Pharmacol. 689, 72-80 (2012).
207. 2+ signaling and caspase-3 activity in neuronal PC12 cells. Cell. Mol. Neurobiol. 33, 205-212 (2013).
208. Murata, M., Hasegawa, K. & Kanazawa, I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68, 45-50 (2007).
209. Ulusoy, G. K. et al. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease. Brain Res. Bull. 85, 380-384 (2011).
210. Haddadi, R., Mohajjel Nayebi, A. & Brooshghalan, S. E. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi- parkinsonian rats. Neurosci. Lett. 555, 106-111 (2013).
211. Foltynie, T. & Aviles-Olmos, I. Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic. Alzheimers Dement. 10 (Suppl. 1), S38-S46 (2014).
212. Schneider, A. et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J. Clin. Invest. 115, 2083-2098 (2005).
213. Watson, F. L. et al. Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. Nat. Neurosci. 4, 981-988 (2001).
214. Jung, K.-H. et al. Granulocyte colony-stimulating factor stimulates neurogenesis via vascular endothelial growth factor with STAT activation. Brain Res. 1073-1074, 190-201 (2006).
215. Hartung, T. Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr. Opin. Hematol. 5, 221-225 (1998).
216. Meuer, K. et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J. Neurochem. 97, 675-686 (2006).
217. Lee, S.-T. et al. Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease. Brain Res. 1194, 130-137 (2008).
218. Xue, Y.-Q., Zhao, L.-R., Guo, W.-P. & Duan, W.-M. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 146, 1245-1258 (2007).
219. Pedroso, I. et al. Use of Cuban recombinant human erythropoietin in Parkinson's disease treatment. MEDICC Rev. 14, 11-17 (2012).
220. Jang, W. et al. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease. J. Neurol. Sci. 337, 47-54 (2014).